<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="cd522f94-c11b-434b-9a98-645f44e6368a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET.<br/> <br/>ZAVZPRET™ (zavegepant) nasal spray <br/>Initial U.S. Approval: 2023</title>
   <effectiveTime value="20250502"/>
   <setId root="1191475f-e999-49f4-a805-93ad08596b1b"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="829076905" root="1.3.6.1.4.1.519.1"/>
            <name>U.S. Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="113480771" root="1.3.6.1.4.1.519.1"/>
                  <name>Pfizer Inc</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="403377f9-9e30-4476-ab5e-9a8f2f0fa6fd"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240827"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63539-135" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZAVZPRET</name>
                        <formCode code="C42989" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SPRAY"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>zavegepant</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="0.1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="000QCM6HAL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ZAVEGEPANT HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="ODU3ZAZ94J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ZAVEGEPANT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.59"/>
                              <denominator unit="mL" value="0.1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AB6MNQ6J6L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCCINIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="1.25"/>
                              <denominator unit="mL" value="0.1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63539-135-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="63539-135-02" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20230601"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216386" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230601"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38284" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NASAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_F85AE51B-4BD4-4E58-85F0-0391BFF26234">
               <id root="7c82e557-f213-4d00-b247-3fb238463014"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <table styleCode="Noautorules" width="100%">
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Warnings and Precautions (<linkHtml href="#ID_989e121a-9f3e-474b-80e4-fc1dd3788562">5.2</linkHtml>, <linkHtml href="#ID_b6275205-a575-417f-b46e-7d42ca37260c">5.3</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="bottom">
                                    <paragraph>3/2025</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="fa885bdb-8d39-4542-bf4d-8545bdb1e62e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>
                  </paragraph>
                  <paragraph>ZAVZPRET is not indicated for the preventive treatment of migraine.</paragraph>
               </text>
               <effectiveTime value="20230309"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use </content>
                        </paragraph>
                        <paragraph>ZAVZPRET is not indicated for the preventive treatment of migraine. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="858b680f-dd3a-4f67-bbd7-21b6abe267b4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230309"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>The recommended dose is 10 mg given as a single spray in one nostril, as needed. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>The maximum dose in a 24-hour period is 10 mg (one spray). (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>The safety of treating more than 8 migraines in a 30-day period has not been established. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="e9719330-d262-44ef-9d0f-0e0f582f6c2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Dosing Information</title>
                     <text>
                        <paragraph>The recommended dose of ZAVZPRET is 10 mg given as a single spray in one nostril, as needed.</paragraph>
                        <paragraph>The maximum dose that may be given in a 24-hour period is 10 mg (one spray). The safety of treating more than 8 migraines in a 30-day period has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="f37e8c91-27cd-4f61-9cee-107228359f2b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Nasal spray: 10 mg of zavegepant per device. Each unit-dose nasal spray device delivers a single spray containing 10 mg of zavegepant.</paragraph>
               </text>
               <effectiveTime value="20230309"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Nasal spray: 10 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="a8d0eeb0-4707-4942-96d4-e3ee8b61523d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ZAVZPRET is contraindicated in patients with a history of hypersensitivity reaction to zavegepant or any of the components of ZAVZPRET <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20230309"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with a history of hypersensitivity reaction to zavegepant or to any of the components of ZAVZPRET. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="aa7b8550-7273-4b94-9b2a-eac2f9081689"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy. Hypersensitivity Reactions including facial swelling and urticaria have occurred with ZAVZPRET. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypertension: New-onset or worsening of pre-existing hypertension may occur. (<linkHtml href="#ID_989e121a-9f3e-474b-80e4-fc1dd3788562">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur. (<linkHtml href="#ID_b6275205-a575-417f-b46e-7d42ca37260c">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="1e904810-fcbf-49a9-9427-dfb0dcb3589a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including facial swelling and urticaria, have occurred in patients treated with ZAVZPRET in clinical studies. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_989e121a-9f3e-474b-80e4-fc1dd3788562">
                     <id root="1fe51470-82fd-40ff-8c27-ef29dbe4f635"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.2	Hypertension</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists in the postmarketing setting. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Some of the patients receiving a CGRP antagonist who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor patients treated with ZAVZPRET for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of ZAVZPRET is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b6275205-a575-417f-b46e-7d42ca37260c">
                     <id root="822c7ec5-2cca-4635-9d90-00dde6ba1a30"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.3	Raynaud’s Phenomenon</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In reported cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">ZAVZPRET should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="12186156-90c9-4723-8612-3f66e947f67b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hypertension <content styleCode="italics">[see <linkHtml href="#ID_989e121a-9f3e-474b-80e4-fc1dd3788562">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Raynaud’s Phenomenon <content styleCode="italics">[see <linkHtml href="#ID_b6275205-a575-417f-b46e-7d42ca37260c">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (at least 2% of patients treated with ZAVZPRET and greater than placebo) were taste disorders, nausea, nasal discomfort, and vomiting. (<linkHtml href="#S6.1">6.1</linkHtml>)<br/> </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="aade3300-3bb5-46ac-8963-de5aef00a661"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The safety of ZAVZPRET for the acute treatment of migraine in adults has been evaluated in two randomized, double-blind, placebo-controlled trials (Study 1 and Study 2) in patients with migraine who received one 10 mg dose of ZAVZPRET nasal spray (N=1023) or placebo (N=1056) <content styleCode="italics">[see <linkHtml href="#ID_CD86022B-2709-4B3E-8322-79FD52A4C296">Clinical Studies (14)</linkHtml>]</content>. Approximately 83% were female, 81% were White, 20% were Hispanic or Latino, and 15% were Black. The mean age at study entry was 41 years (range 18-79 years of age).</paragraph>
                        <paragraph>Adverse reactions in Study 1 and 2 are shown in Table 1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Adverse Reactions Occurring in At Least 2% of Patients Treated with ZAVZPRET and at a Frequency Greater than Placebo in Study 1 and 2</content>
                        </paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">ZAVZPRET</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=1023</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=1056</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Taste Disorders<footnote ID="_Ref129341144">Taste disorders includes dysgeusia and ageusia</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nasal Discomfort</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>&lt;1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Hypersensitivity, including facial swelling and urticaria, occurred in less than 1% of patients treated with ZAVZPRET <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Long-term safety was assessed in an open-label extension study. That study evaluated 603 patients, dosing intermittently for up to one year, including 360 patients who were exposed to ZAVZPRET 10 mg for at least 6 months, and 298 who were exposed for at least one year, all of whom treated an average of at least two migraine attacks per month.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d2162e5d-08ce-4ddc-80ed-513b6a95af31">
                     <id root="3552a07f-f210-4b14-96b8-22a079eac9c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of ZAVZPRET. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders</content>: Hypertension <content styleCode="italics">[see <linkHtml href="#ID_989e121a-9f3e-474b-80e4-fc1dd3788562">Warnings and Precautions (5.2)</linkHtml>]</content>, Raynaud’s phenomenon <content styleCode="italics">[see <linkHtml href="#ID_b6275205-a575-417f-b46e-7d42ca37260c">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="944fddb5-f2ed-457d-9a9f-38c7d00d6a16"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Avoid use with drugs that inhibit OATP1B3 or NTCP transporters. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Avoid use with drugs that induce OATP1B3 or NTCP transporters. (<linkHtml href="#ID_a856e49a-b14e-430d-991f-f96cfb2b3ab5">7.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration. (<linkHtml href="#ID_52d65ea8-84a8-427a-83a4-07eae494df1f">7.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="752a91ed-2387-45b4-8cae-2f51c00f30ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	OATP1B3 or NTCP Inhibitors</title>
                     <text>
                        <paragraph>Concomitant administration of ZAVZPRET with inhibitors of the organic anion transporting polypeptide 1B3 (OATP1B3) or sodium taurocholate co-transporting polypeptide (NTCP) transporters may result in a significant increase in zavegepant exposure. Avoid concomitant administration of ZAVZPRET with drugs that inhibit OATP1B3 or NTCP transporters <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a856e49a-b14e-430d-991f-f96cfb2b3ab5">
                     <id root="03a133f3-bf5d-45a9-a23d-6a881ae0f063"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	OATP1B3 or NTCP Inducers </title>
                     <text>
                        <paragraph>Concomitant administration of ZAVZPRET with inducers of OATP1B3 or NTCP transporters may result in a decrease in zavegepant exposure. Avoid concomitant administration of ZAVZPRET with drugs that induce OATP1B3 or NTCP transporters <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_52d65ea8-84a8-427a-83a4-07eae494df1f">
                     <id root="26b28a04-f18c-462c-bd16-29a541a7ae69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Intranasal Decongestants </title>
                     <text>
                        <paragraph>Concomitant administration of ZAVZPRET with intranasal decongestants may decrease the absorption of zavegepant. Avoid concomitant administration of intranasal decongestants with ZAVZPRET. When concomitant use is unavoidable, intranasal decongestants should be administered at least 1 hour after ZAVZPRET administration <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="8190fa94-af82-415d-b511-02ec691b13fa"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Avoid use in patients with severe hepatic impairment. (<linkHtml href="#ID_45852564-141e-4d8f-8c4b-5fb39edf379a">8.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Avoid use in patients with CLcr &lt; 30 mL/min. (<linkHtml href="#ID_f4cfa97e-f33b-410f-a6df-818531577797">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="2aeb5cac-73eb-4f41-b71a-17361e10699d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate data on the developmental risk associated with the use of ZAVZPRET in pregnant women. No adverse developmental effects were observed following subcutaneous administration of zavegepant to pregnant animals at doses associated with plasma exposures higher than those used clinically <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. </paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated rate of major birth defects (2.2 to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                        </paragraph>
                        <paragraph>Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.</paragraph>
                        <paragraph ID="data">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Subcutaneous administration of zavegepant to pregnant rats (0, 10, 20, or 40 mg/kg/day) or rabbits (0, 20, 40, or 60 mg/kg/day) during the period of organogenesis resulted in no adverse effects on embryofetal development. Plasma exposures (AUC) at the highest doses tested were approximately 4000 times that in humans at the maximum recommended human dose (MRHD) of 10 mg/day. </paragraph>
                        <paragraph>Subcutaneous administration of zavegepant (0, 5, 10, or 20 mg/kg/day) to rats throughout pregnancy and lactation resulted in no adverse effects on pre- and postnatal development. Plasma exposure (AUC) at the highest dose tested was approximately 2500 times that in humans at the MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="d3e89be2-d61d-4150-9d2b-e5d668958e33"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <text>
                        <paragraph>There are no data on the presence of zavegepant or its metabolites in human milk, the effects of zavegepant on the breastfed infant, or the effects of zavegepant on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZAVZPRET and any potential adverse effects on the breastfed infant from ZAVZPRET or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="d2e564d9-f34e-4101-997e-83a64c3637e3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established. </paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="60e581e3-caba-4b80-b701-91da9d433523"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of ZAVZPRET did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.</paragraph>
                        <paragraph>In a limited number of patients 65 years of age and older, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_45852564-141e-4d8f-8c4b-5fb39edf379a">
                     <id root="4a3835ce-dcf9-4b21-a25a-091d233528d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Hepatic Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment of ZAVZPRET is necessary in patients with mild hepatic impairment (Child-Pugh Class A) or moderate hepatic impairment (Child-Pugh Class B). ZAVZPRET has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Avoid use of ZAVZPRET in patients with severe hepatic impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f4cfa97e-f33b-410f-a6df-818531577797">
                     <id root="1f8c6bd1-7e60-4982-a294-980941414913"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7	Renal Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment of ZAVZPRET is necessary in patients with estimated creatine clearance (CLcr) 30 mL/min or greater. Avoid use of ZAVZPRET in patients with CLcr less than 30 mL/min <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5F8FB1E3-3117-4E91-B8C4-C0160AF96229">
               <id root="2602861c-5fbc-401b-9b78-3e2d832e7916"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>ZAVZPRET (zavegepant) nasal spray contains zavegepant hydrochloride, a calcitonin gene-related peptide receptor antagonist. Zavegepant hydrochloride is described chemically as (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl) piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl) piperidine-1-carboxamide hydrochloride and its structural formula is:</paragraph>
                  <renderMultiMedia ID="id-25797725" referencedObject="ID_59fcd7a1-cd5b-47d1-8784-1a3f43e22602"/>
                  <paragraph>Its molecular formula is C<sub>36</sub>H<sub>46</sub>N<sub>8</sub>O<sub>3</sub>․HCl, representing a molecular weight of 675.28 g/mol. Zavegepant free base has a molecular weight of 638.82 g/mol. Zavegepant hydrochloride is a white to off-white powder, freely soluble in water, and has pKa values of 4.8 and 8.8. </paragraph>
                  <paragraph>Each unit-dose ZAVZPRET device for nasal administration delivers 10 mg of zavegepant (equivalent to 10.6 mg of zavegepant hydrochloride) in a buffered aqueous solution containing dextrose, hydrochloric acid, sodium hydroxide, and succinic acid in water for injection. The solution has a pH of 5.3 to 6.7.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="ID_59fcd7a1-cd5b-47d1-8784-1a3f43e22602">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="70f44694-e982-4f4d-afc0-87a4064f7480"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="S12.1">
                     <id root="e44d7667-ac5b-40ba-8158-6d734bda502b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="a9a5069c-363c-49d4-a717-5760dfc7688c"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The relationship between pharmacodynamic activity and the mechanism by which zavegepant exerts its clinical effects is unknown.</paragraph>
                        <paragraph>No clinically relevant differences in resting blood pressure were observed when zavegepant was concomitantly administered with sumatriptan (12 mg subcutaneous, given as two 6 mg doses separated by one hour) compared with sumatriptan alone to healthy volunteers.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At a dose up to 4 times the recommended daily dose, zavegepant does not prolong the QT interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="e28fe12c-475d-4980-bf1a-70c5e9c9686c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption </content>
                        </paragraph>
                        <paragraph>Peak plasma concentration of zavegepant was observed at approximately 30 minutes after a single 10 mg dose of the nasal spray. After nasal spray administration of zavegepant, the absolute bioavailability is approximately 5%. </paragraph>
                        <paragraph>Zavegepant given as a single dose of the nasal spray displays slightly less than dose-proportional pharmacokinetics up to 40 mg (approximately 4 times the recommended dosage of 10 mg). </paragraph>
                        <paragraph>Following once daily dosing of ZAVZPRET for 14 days there was no evidence of zavegepant accumulation. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution </content>
                        </paragraph>
                        <paragraph>The mean apparent volume of distribution of intranasal zavegepant is approximately 1774 L. Plasma protein binding of zavegepant is approximately 90%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Zavegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6, in vitro. After single IV dose of 5 mg [<sup>14</sup>C]-zavegepant, unchanged zavegepant was the most prevalent (approximately 90%) circulating component in the human plasma. No major metabolites (i.e., greater than 10%) of zavegepant were detected in plasma.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>The effective half-life of zavegepant following a 10 mg dose of the nasal spray is 6.55 hours. The mean apparent clearance of intranasal zavegepant is 266 L/h. Zavegepant is excreted mostly via the biliary/fecal route, while the renal route is a minor route of elimination. Following a single intravenous dose of 5 mg [<sup>14</sup>C]-zavegepant to healthy male subjects, approximately 80% and 11% of the dose was recovered as unchanged zavegepant in feces and urine, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>In a dedicated clinical study comparing the pharmacokinetics of zavegepant in subjects with moderate hepatic impairment (Child-Pugh B) to that of normal subjects (matched healthy controls), zavegepant C<sub>max</sub> was 16% higher and AUC was 1.9-fold higher in patients with moderate hepatic impairment. These changes in exposures are not expected to be clinically significant, based on clinical safety experience and minimal accumulation of drug exposures. The impact of severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of zavegepant was not studied <content styleCode="italics">[see <linkHtml href="#ID_45852564-141e-4d8f-8c4b-5fb39edf379a">Use in Specific Populations (8.6)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>The renal route plays a minor role in the clearance of zavegepant. No clinically significant effect on the pharmacokinetics of zavegepant is expected in subjects with estimated creatinine clearance (CLcr) 30 mL/min or greater. In patients with CLcr 15 to 29 mL/min, accumulation of uremic solutes can cause an increase in zavegepant exposures by inhibiting OATP transporters. Zavegepant has not been studied in patients with CLcr less than 15 mL/min <content styleCode="italics">[see <linkHtml href="#ID_f4cfa97e-f33b-410f-a6df-818531577797">Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Other Specific Populations</content>
                        </paragraph>
                        <paragraph>Age, sex, race, ethnicity, and body weight did not show clinically significant effects on the pharmacokinetics of zavegepant. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Enzymes </content>
                           </content>
                        </paragraph>
                        <paragraph>Zavegepant is a substrate of CYP3A4 and to a lesser extent CYP2D6. Zavegepant is not an inducer of CYP1A2, 2B6, or 3A4, or an inhibitor of CYP1A2, CYP2C9, 2C19, 2B6, 2D6, 2C8, and 3A4 at clinically relevant concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Transporters </content>
                           </content>
                        </paragraph>
                        <paragraph>Zavegepant is a substrate for OATP1B3 and NTCP <content styleCode="italics">(see <linkHtml href="#in_vivo_studies">In Vivo studies</linkHtml>)</content>.</paragraph>
                        <paragraph>Zavegepant is also a substrate for the transporters P-gp, MATE1, and MATE2-K. Considering the minor contribution of the renal pathway in the clearance of zavegepant, coadministration of zavegepant with inhibitors of P-gp, MATE1, and MATE2-K inhibitors is not expected to result in a clinically significant effect on zavegepant pharmacokinetics. </paragraph>
                        <paragraph>Zavegepant is not a substrate for BCRP, OATP1B1, OAT1, OAT3, OCT2, BSEP, MRP2, MRP3, and MRP4. </paragraph>
                        <paragraph>Zavegepant is an inhibitor of OCT2, MATE1, and MATE2-K, but drug interactions for ZAVZPRET are not expected at clinically relevant concentrations. Zavegepant is not an inhibitor of P-gp, BCRP, OAT1, OAT3, OATP1B1, and OATP1B3. </paragraph>
                        <paragraph ID="in_vivo_studies">
                           <content styleCode="italics">In Vivo Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">CYP3A4 Inhibitors </content>
                           </content>
                        </paragraph>
                        <paragraph>Concomitant administration of a single dose of 10 mg ZAVZPRET with itraconazole (a strong CYP3A4 and P-gp inhibitor), at steady state did not result in a clinically relevant effect on the exposures of zavegepant. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">OATP1B3 or NTCP Inhibitors</content>
                           </content>
                        </paragraph>
                        <paragraph>Concomitant administration of a single oral dose of 100 mg zavegepant with rifampin (an OATP1B3, NTCP inhibitor and a strong CYP3A inducer), at steady state resulted in increased zavegepant exposure (AUC by 2.3-fold and C<sub>max</sub> by 2.2-fold). The observed change in zavegepant exposures is a composite effect of inhibition of OATP1B3 and NTCP transporters as well as induction of CYP3A enzymes. Concomitant administration of ZAVZPRET with inhibitors of OATP1B3 or NTCP transporters may result in a significant increase in zavegepant exposure <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">OATP1B3 or NTCP Inducers </content>
                           </content>
                        </paragraph>
                        <paragraph>Concomitant administration of ZAVZPRET with inducers of OATP1B3 or NTCP transporters has not been studied. However, since zavegepant is a substrate of OATP1B3 and NTCP, concomitant administration with inducers of these transporters may result in decreased zavegepant exposure <content styleCode="italics">[see <linkHtml href="#ID_a856e49a-b14e-430d-991f-f96cfb2b3ab5">Drug Interactions (7.2)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Intranasal Decongestants</content>
                           </content>
                        </paragraph>
                        <paragraph>The effect of concomitant intranasal decongestants on the pharmacokinetics of zavegepant nasal spray has not been evaluated. Concomitant administration of intranasal decongestants may decrease the systemic exposure of zavegepant and potentially the efficacy of zavegepant <content styleCode="italics">[see <linkHtml href="#ID_52d65ea8-84a8-427a-83a4-07eae494df1f">Drug Interactions (7.3)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Other Drugs</content>
                           </content>
                        </paragraph>
                        <paragraph>No significant pharmacokinetic interactions were observed when zavegepant was concomitantly administered with oral contraceptives (ethinyl estradiol) or sumatriptan <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="773a66dc-cc57-4c58-b52f-3acc218670bf"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250321"/>
               <component>
                  <section ID="S13.1">
                     <id root="005bd167-9a2c-4f3e-8e7e-1e38b8d49e69"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Intranasal administration of zavegepant (0, 0.3, 0.8, or 2.5 mg/day) to Tg.rasH2 mice for 26 weeks resulted in no evidence of drug-related tumors. </paragraph>
                        <paragraph>Intranasal administration of zavegepant (0, 2, 9, or 18.8 mg/kg/day) to rats for up to 96 weeks resulted in no evidence of drug-related tumors. Plasma exposure (AUC) at the highest dose tested was approximately 140 times that in humans at the maximum recommended human dose (MRHD) of 10 mg/day. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Zavegepant was negative in <content styleCode="italics">in vitro</content> (bacterial reverse mutation, chromosomal aberration in Chinese hamster ovary cells) and <content styleCode="italics">in vivo</content> (rat micronucleus) assays.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Subcutaneous administration of zavegepant (0, 5, 15, or 25 mg/kg/day) to male and female rats prior to and during mating and continuing in females to gestation day 7 resulted in no adverse effects on fertility or reproductive performance. Plasma exposures (AUC) at the highest dose tested were approximately 2800 times that in humans at MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20250321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_CD86022B-2709-4B3E-8322-79FD52A4C296">
               <id root="55eee9b5-9fe0-4f62-9e89-fa47bd65da96"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>The efficacy of ZAVZPRET for the acute treatment of migraine with or without aura in adults was demonstrated in two randomized, double-blind, placebo-controlled trials (Study 1 and Study 2). In both studies, patients were instructed to treat a migraine of moderate to severe headache pain intensity. Rescue medication (i.e., NSAIDs, acetaminophen, and/or an antiemetic) was allowed 2 hours after the initial treatment. Other forms of rescue medication such as triptans were not allowed within 48 hours of initial treatment. In Study 1 and Study 2, 13.4% and 13.6% of patients were taking preventive medications for migraine at baseline, respectively. None of the patients were on concomitant preventive medication that act on the CGRP pathway.</paragraph>
                  <paragraph>In Study 1 (NCT04571060), patients were randomized to receive a single dose of ZAVZPRET 10 mg (N=623) or placebo (N=646). Efficacy was demonstrated with ZAVZPRET 10 mg by an effect on the coprimary endpoints of pain freedom and most bothersome symptom (MBS) freedom at 2 hours after a single dose, compared to placebo. Pain freedom was defined as a reduction of moderate or severe headache pain to no headache pain, and MBS freedom was defined as the absence of the self-identified MBS (i.e., photophobia, phonophobia, or nausea). The most common MBS reported before dosing was photophobia (55%), followed by nausea (28%), and phonophobia (16%).</paragraph>
                  <paragraph>In Study 1, the percentage of patients achieving headache pain freedom and MBS freedom 2 hours after a single dose was statistically significantly greater in patients who received ZAVZPRET compared to those who received placebo (Table 2).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 2: Efficacy Endpoints in Study 1</content>
                  </paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="33%"/>
                     <col width="33%"/>
                     <col width="33%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ZAVZPRET</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">10 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Pain Free at 2 hours</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     n/N<footnote ID="_Ref129366417">n=number of responders/N=number of patients in that treatment group</footnote>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>147/623</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>96/646</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % Responders</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>23.6</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>14.9</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Difference from placebo (%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>8.8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     p-value</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>&lt;0.001</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">MBS</content>
                                 <footnote ID="_Ref129366453">MBS = most bothersome symptoms of photophobia, phonophobia, or nausea.</footnote>
                                 <content styleCode="bold"> Free at 2 hours</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     n/N<footnoteRef IDREF="_Ref129366417"/>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>247/623</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>201/646</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % Responders</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>39.6</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>31.1</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Difference from placebo (%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>8.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>     p-value</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>0.001</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Figures 1 and 2 present the percentage of patients achieving migraine pain freedom and MBS freedom within 2 hours following treatment in Study 1.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Percentage of Patients Achieving Pain Freedom within 2 Hours in Study 1</content>
                  </paragraph>
                  <renderMultiMedia ID="id319078959" referencedObject="a25badad-0206-4e8a-8ba5-70c163d96e7f"/>
                  <paragraph>
                     <content styleCode="bold">Figure 2: Percentage of Patients Achieving MBS Freedom within 2 Hours in Study 1</content>
                  </paragraph>
                  <renderMultiMedia ID="id-498885801" referencedObject="ID_55d5d52b-6209-4ea6-80c1-41069d1530cb"/>
                  <paragraph>In Study 1, statistically significant effects of ZAVZPRET compared to placebo were demonstrated for the additional efficacy endpoints of pain relief at 2 hours post-dose, return to normal function at 2 hours post-dose, sustained pain freedom from 2 to 48 hours post-dose (Table 3), and phonophobia and photophobia freedom at 2 hours post-dose. Pain relief was defined as a reduction in migraine pain from moderate or severe severity to mild or none. The measurement of the percentage of patients reporting normal function at two hours after dosing was derived from a single item questionnaire, asking patients to select one response on a 4-point scale: normal function, mild impairment, severe impairment, or required bedrest.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 3: Additional Efficacy Endpoints in Study 1</content>
                  </paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="33%"/>
                     <col width="33%"/>
                     <col width="33%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ZAVZPRET</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">10 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Pain Relief at 2 hours</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     n/N<footnote ID="_Ref129348437">n=number of responders/N=number of patients in that treatment group</footnote>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>366/623</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>321/646</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % Responders</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>58.7</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>49.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Difference from placebo (%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>9.0</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     p-value</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0.001</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Percentage of Patients Reporting Normal Function at 2 hours</content>
                                 <footnote ID="_Ref129348472">Includes patients with functional disability at time of dosing, according to the functional disability scale.</footnote>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     n/N<footnoteRef IDREF="_Ref129348437"/>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>204/570</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>152/593</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % Responders</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>35.8</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>25.6</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Difference from placebo (%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>10.2</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     p-value</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>&lt;0.001</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Sustained Pain Freedom from 2 to 48 hours</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     n/N<footnoteRef IDREF="_Ref129348437"/>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>77/623</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>56/646</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % Responders</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>12.4</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>8.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Difference from placebo (%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>3.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>     p-value</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>0.031</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The incidence of photophobia and phonophobia was reduced following administration of ZAVZPRET 10 mg as compared to placebo.</paragraph>
                  <paragraph>In Study 2 (NCT03872453), patients were randomized to receive a single dose of ZAVZPRET 10 mg (n=391) or placebo (n=401). </paragraph>
                  <paragraph>In Study 2, statistically significant efficacy was demonstrated with ZAVZPRET 10 mg by an effect on the coprimary endpoints of pain freedom and most bothersome symptom (MBS) freedom at 2 hours after a single dose, compared to placebo. Pain freedom was observed in 22.5% of patients receiving ZAVZPRET and 15.5% of patients receiving placebo (p-value = 0.011). MBS freedom was observed in 41.9% of patients receiving ZAVZPRET and 33.7% of patients receiving placebo (p-value = 0.016). The most common MBS reported before dosing was photophobia (53%), followed by nausea (31%), and phonophobia (15%).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 4: Efficacy Endpoints in Study 2</content>
                  </paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="33%"/>
                     <col width="33%"/>
                     <col width="33%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ZAVZPRET</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">10 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Pain Free at 2 hours</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     n/N<footnote ID="_Ref129348710">n=number of responders/N=number of patients in that treatment group</footnote>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>88/391</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>62/401</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % Responders</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>22.5</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>15.5</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Difference from placebo (%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>7.0</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     p-value</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0.011</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">MBS</content>
                                 <footnote ID="_Ref129348704">MBS = most bothersome symptoms of photophobia, phonophobia, or nausea.</footnote>
                                 <content styleCode="bold"> Free at 2 hours</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     n/N<footnoteRef IDREF="_Ref129348710"/>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>164/391</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>135/401</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % Responders</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>41.9</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>33.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Difference from placebo (%)</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>8.3</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>     p-value</paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>0.016</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Figure 3: Percentage of Patients Achieving Pain Freedom within 2 Hours in Study 2</content>
                  </paragraph>
                  <renderMultiMedia ID="id-899368995" referencedObject="ID_03da35d1-ad2a-4a25-a5cb-412f3fcb04ce"/>
                  <paragraph>
                     <content styleCode="bold">Figure 4: Percentage of Patients Achieving MBS Freedom within 2 Hours in Study 2</content>
                  </paragraph>
                  <renderMultiMedia ID="id762032785" referencedObject="ID_5e8586a5-e8c2-433c-88b8-c4552cf9140a"/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="a25badad-0206-4e8a-8ba5-70c163d96e7f">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_55d5d52b-6209-4ea6-80c1-41069d1530cb">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_03da35d1-ad2a-4a25-a5cb-412f3fcb04ce">
                     <text>Figure 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_5e8586a5-e8c2-433c-88b8-c4552cf9140a">
                     <text>Figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="36cce592-efd7-485a-956d-f5bcd2d9abf7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20230309"/>
               <component>
                  <section ID="ID_c3e605c2-582f-4464-84e0-ee4fa701efd5">
                     <id root="59405ac3-30f4-4265-b4ee-78b0c9215196"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1	How Supplied</title>
                     <text>
                        <paragraph>ZAVZPRET nasal spray (NDC 0069-3500-01) contains 10 mg zavegepant and is supplied as a ready-to-use, unit-dose disposable device.</paragraph>
                        <paragraph>Each carton contains 6 units (NDC 0069-3500-02) and a Patient Information and Instructions for Use leaflet.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7a52c157-6797-4a8f-96b3-9bf7f977a22b">
                     <id root="a14e737b-b3a9-4d85-851b-4c27348e832a"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2	Storage and Handling</title>
                     <text>
                        <paragraph>Store ZAVZPRET at controlled room temperature, 20°C to 25°C (68°F to 77°F); with excursions permitted between 15°C to 30°C (59°F to 86°F) <content styleCode="italics">[see USP controlled room temperature]</content>. </paragraph>
                        <paragraph>Do not freeze. Do not test spray, prime, or press the plunger before use.</paragraph>
                     </text>
                     <effectiveTime value="20230309"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="901aa3c3-a4a7-48e3-8a85-2a524ea359ad"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients about the signs and symptoms of hypersensitivity reactions after administration of ZAVZPRET. Advise patients to contact their healthcare provider immediately if signs or symptoms of hypersensitivity reactions occur <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypertension</content>
                  </paragraph>
                  <paragraph>Inform patients that hypertension can develop or pre-existing hypertension can worsen with ZAVZPRET, and that they should contact their healthcare provider if they experience elevation in their blood pressure <content styleCode="italics">[see <linkHtml href="#ID_989e121a-9f3e-474b-80e4-fc1dd3788562">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Raynaud’s Phenomenon</content>
                  </paragraph>
                  <paragraph>Inform patients that Raynaud’s phenomenon can develop or worsen with ZAVZPRET. Advise patients to discontinue ZAVZPRET and contact their healthcare provider if they experience signs or symptoms of Raynaud’s phenomenon <content styleCode="italics">[see <linkHtml href="#ID_b6275205-a575-417f-b46e-7d42ca37260c">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients to speak with their healthcare provider about any prescription or over-the-counter medications or herbal supplements that they take or plan to take. Inform patients that if they need to use an intranasal decongestant it should be administered at least 1 hour after ZAVZPRET administration <content styleCode="italics">[see <linkHtml href="#ID_52d65ea8-84a8-427a-83a4-07eae494df1f">Drug Interactions (7.3)</linkHtml>]</content>. </paragraph>
                  <paragraph>This product’s labeling may have been updated. For the most recent prescribing information, please visit <linkHtml href="http://www.pfizer.com">www.pfizer.com</linkHtml>.</paragraph>
                  <renderMultiMedia ID="id1617863420" referencedObject="ID_2dc51a71-2a58-4fbf-a49c-ee8f21eaf76b"/>
                  <paragraph>LAB-1544-2.0</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="ID_2dc51a71-2a58-4fbf-a49c-ee8f21eaf76b">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cf7c8f6f-47ee-41d7-96bd-e11db8595e69">
               <id root="3b9c9185-d3cb-4466-8f46-e3437bebf8a4"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Package Insert </title>
               <text>
                  <table width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION </content>
                                 <br/>ZAVZPRET™ (zav-spret)</paragraph>
                              <paragraph>(zavegepant)</paragraph>
                              <paragraph>nasal spray</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What is ZAVZPRET?</content>
                  </paragraph>
                  <paragraph>ZAVZPRET is a prescription medicine used in adults for the acute treatment of migraine attacks with or without aura.</paragraph>
                  <paragraph>ZAVZPRET is not used to prevent migraine attacks.</paragraph>
                  <paragraph>It is not known if ZAVZPRET is safe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not use ZAVZPRET if you are:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>allergic to zavegepant, or any of the ingredients in ZAVZPRET.</item>
                  </list>
                  <paragraph>See the end of this leaflet for a complete list of ingredients in ZAVZPRET.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you use ZAVZPRET, tell your healthcare provider about all of your medical conditions, including if you: </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>have high blood pressure.</item>
                     <item>
                        <caption>•</caption>have circulation problems in your fingers and toes.</item>
                     <item>
                        <caption>•</caption>have kidney problems.</item>
                     <item>
                        <caption>•</caption>have liver problems.</item>
                     <item>
                        <caption>•</caption>are pregnant or plan to become pregnant. It is not known if ZAVZPRET will harm your unborn baby.</item>
                     <item>
                        <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known whether ZAVZPRET passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you use ZAVZPRET. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I use ZAVZPRET? </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Use ZAVZPRET exactly how your healthcare provider tells you to use it.</item>
                     <item>
                        <caption>•</caption>See the Instructions for Use for complete information on how to use ZAVZPRET nasal spray.</item>
                     <item>
                        <caption>•</caption>ZAVZPRET is given in the nose (nasal) only.</item>
                     <item>
                        <caption>•</caption>Each ZAVZPRET only sprays 1 time and cannot be reused. <content styleCode="bold">Do not</content> test or prime the nasal spray before use.</item>
                     <item>
                        <caption>•</caption>Each dose of ZAVZPRET is provided in an individual pack. Use all of the medicine in 1 pack for a complete dose.</item>
                     <item>
                        <caption>•</caption>The recommended dose is 10 mg given as a single spray in one nostril.</item>
                     <item>
                        <caption>•</caption>Do not use more than 1 spray (10 mg) of ZAVZPRET nasal spray in a 24-hour period.</item>
                     <item>
                        <caption>•</caption>It is not known if it is safe to use more than 8 sprays (doses) of ZAVZPRET in 30 days.</item>
                     <item>
                        <caption>•</caption>Avoid using intranasal decongestants with ZAVZPRET. If you have to use an intranasal decongestant, use it at least 1 hour after using ZAVZPRET.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of ZAVZPRET? </content>
                  </paragraph>
                  <paragraph>ZAVZPRET may cause serious side effects including:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Allergic reactions.</content> Allergic reactions, including hives and swelling of the face, can happen after you use ZAVZPRET. Call your healthcare provider or get emergency help right away if you have any of the following symptoms, which may be part of an allergic reaction:<list listType="unordered">
                           <item>
                              <caption>o</caption>swelling of the face, mouth, tongue, or throat</item>
                           <item>
                              <caption>o</caption>trouble breathing</item>
                        </list>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">High blood pressure.</content> High blood pressure or worsening of high blood pressure can happen after you use ZAVZPRET. Contact your healthcare provider if you have an increase in blood pressure.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Raynaud’s phenomenon.</content> A type of circulation problem can worsen or happen after you use ZAVZPRET. Raynaud’s phenomenon can lead to your fingers or toes feeling numb, cool, or painful, or changing color from pale, to blue, to red. Contact your healthcare provider if these symptoms occur.</item>
                  </list>
                  <paragraph>The most common side effects of ZAVZPRET are:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>unusual taste</item>
                     <item>
                        <caption>•</caption>nausea </item>
                     <item>
                        <caption>•</caption>nasal discomfort</item>
                     <item>
                        <caption>•</caption>vomiting</item>
                  </list>
                  <paragraph>These are not the only possible side effects of ZAVZPRET. </paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store ZAVZPRET? </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Store ZAVZPRET in the blister package that it comes in.</item>
                     <item>
                        <caption>•</caption>Store ZAVZPRET at room temperature between 68°F to 77°F (20°C to 25°C). </item>
                     <item>
                        <caption>•</caption>Do not freeze.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep ZAVZPRET and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of ZAVZPRET: </content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZAVZPRET for a condition for which it was not prescribed. Do not give ZAVZPRET to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZAVZPRET that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in ZAVZPRET?</content>
                  </paragraph>
                  <paragraph>Active ingredients in ZAVZPRET: zavegepant</paragraph>
                  <paragraph>Inactive ingredients in ZAVZPRET: dextrose, hydrochloric acid, sodium hydroxide, and succinic acid in water for injection.<br/>
                  </paragraph>
                  <renderMultiMedia ID="id1049966816" referencedObject="ID_01749d62-4a6b-4061-9f63-40c2b5eb755f"/>
                  <paragraph>For more information, go to <linkHtml href="http://www.zavzpret.com">www.zavzpret.com</linkHtml> or call 1-800-438-1985.</paragraph>
                  <paragraph>LAB-1545-2.0</paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="80%"/>
                     <col width="20%"/>
                     <tbody>
                        <tr>
                           <td valign="top">
                              <paragraph>This Patient Information has been approved by the US. Food and Drug Administration</paragraph>
                           </td>
                           <td align="right" valign="top">
                              <paragraph>3/2025</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="ID_01749d62-4a6b-4061-9f63-40c2b5eb755f">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8bb7bad5-c8f6-4570-aaf6-b62c7535684a">
               <id root="23f56085-84b6-4900-b1fb-5d0840e1fca8"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use </title>
               <text>
                  <table styleCode="Noautorules" width="100%">
                     <col width="5%"/>
                     <col width="1%"/>
                     <col width="94%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">ZAVZPRET [zav-spret]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(zavegepant) nasal spray</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">For Nasal Use Only</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">This Instructions for Use contains information on how to give a single dose (10 mg) with ZAVZPRET nasal spray</content>
                              </paragraph>
                              <paragraph>One (1) device delivers a single dose of ZAVZPRET. The device provides 1 spray that should be delivered into 1 nostril.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">ZAVZPRET Device Parts</content>
                              </paragraph>
                              <renderMultiMedia ID="id-189069306" referencedObject="b153d328-b5b0-4a44-b9ee-f25b4962d894"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Important Information You Need to Know Before Dosing with ZAVZPRET</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">For nasal use only</content> (spray into nose).</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> spray in the eyes.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Keep</content> ZAVZPRET and all medicines out of reach of children.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> use if the expiration (EXP) date has passed. Throw away the expired device in the trash if the expiration (EXP) date has passed.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> remove the device from its blister packaging until you are ready to use it.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> test spray, prime, or press the plunger before dosing. Each device is single use and can only be used 1 time. If you press the plunger before dosing, the spray will be lost, and the device will no longer function.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> try to spray (dose) into more than 1 nostril. A dose is 1 spray into 1 nostril. </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> use more than 1 dose in a 24-hour period. Only 1 dose can be used per day. </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> use more than 8 doses per month. A maximum of 8 doses can be used per month. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Storage Information</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">The device should be stored at room temperature</content> between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> freeze.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Keep</content> the device in the sealed blister package until time of use.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Keep</content> ZAVZPRET and all medicines out of reach of children.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Preparing to Dose with ZAVZPRET Nasal Spray</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="middle">
                              <paragraph>
                                 <content styleCode="bold">1</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Gently Blow Your Nose</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>1.1</paragraph>
                           </td>
                           <td colspan="2" valign="middle">
                              <paragraph>Before using ZAVZPRET, blow your nose to clear your nostrils (see <content styleCode="bold">Figure B</content>). This can be done while sitting or standing.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id-1063871318" referencedObject="d9e9ef00-464c-433b-8dd3-fbe78decc27e"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">2</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Remove 1 Blister from the Carton</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>2.1</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Remove 1 blister containing a device from the carton (see <content styleCode="bold">Figure C</content>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id1359930253" referencedObject="e7b2fcf9-33b3-48cc-83da-ecca7910164b"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">3</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Check Expiration Date on the Blister</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>3.1</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Check the expiration date on the blister containing a device (see <content styleCode="bold">Figure D</content>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top"/>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Do not</content> use if the expiration date has passed. Throw away the expired device in the trash if the expiration date has passed.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id464327750" referencedObject="ID_83364e5a-a47b-430b-b69d-6c791bbd5c8c"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">4</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Remove Device from Blister</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>4.1</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Peel open the blister seal from the corner and remove it completely (see <content styleCode="bold">Figure E</content>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>4.2</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Carefully remove the device from the plastic tray.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id-460036401" referencedObject="ID_974e56f1-5412-4eb9-b1df-caa88281cbc7"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Dosing with ZAVZPRET Nasal Spray</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">5</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Check Expiration Date on the Device</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>5.1</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Check the expiration date on the device (see <content styleCode="bold">Figure F</content>). </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> use if the expiration date has passed. Throw away the expired device in the trash if the expiration date has passed.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id-91396272" referencedObject="ID_636e0a63-4fbf-4141-b504-17bb82a2de3d"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">6</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Grip the Device</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>6.1</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Hold the device upright with your thumb on the bottom of the plunger and two fingers on either side of the nozzle (see <content styleCode="bold">Figure G</content>).</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> press the plunger yet. If you press the plunger now, the medicine will spray and be wasted.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id265896411" referencedObject="ID_88ebbd8d-761e-4a12-bab1-35fe0c0cca16"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Dosing with ZAVZPRET Nasal Spray (Continued)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">7</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Close 1 Nostril</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>7.1</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>With your free hand, gently press 1 nostril to close it (see <content styleCode="bold">Figure H</content>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>7.2</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Continue breathing normally through your mouth.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id1804279672" referencedObject="d4cb6639-d524-4d90-9a25-0ad7dec1a806"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">8</content>
                              </paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Insert Spray Nozzle Into Open Nostril</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>8.1</paragraph>
                           </td>
                           <td colspan="2" valign="top">
                              <paragraph>Insert the nozzle into the open nostril as much as you comfortably can (see <content styleCode="bold">Figure I</content>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id1909028678" referencedObject="ID_916d86ae-a8e0-4245-b21a-e4c832651167"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">9</content>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Deliver the Dose by Spraying Into Nostril and Breathing In</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>9.1</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Keep your head level and upright and close your mouth.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> tilt your head.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not</content> lay down while delivering the dose.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>9.2</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Slowly breathe in through your nose as you firmly press the plunger up with your thumb to release the spray (see <content styleCode="bold">Figure J</content>).</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Important:</content> Hold the nozzle firmly in your nose as you deliver the dose. Do not let the nozzle come out when pressing the plunger.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Spray only 1 time into 1 nostril.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id78725019" referencedObject="ID_87873e60-5ce2-4b5a-9027-74b3ad13c5d0"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">10</content>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Remove the Device and Keep Your Head Level for 20 Seconds</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>10.1</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Remove the device from your nostril and your finger from your other nostril.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>10.2</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>While keeping your head level and upright, gently breathe in through your nose and out through your mouth for 10 to 20 seconds (see <content styleCode="bold">Figure K</content>).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">If you feel a drip from your nose, gently sniff so you do not lose any of your dose.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id-443844317" referencedObject="ID_1c1e7c9f-c846-43c5-9669-38b904dedd9e"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Throwing away (Disposing of) Device</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>
                                 <content styleCode="bold">11</content>
                              </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>
                                 <content styleCode="bold">Throw Away Used Device</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top">
                              <paragraph>11.1</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>Throw away the used device into trash (see <content styleCode="bold">Figure L</content>)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" valign="top">
                              <renderMultiMedia ID="id-1001886957" referencedObject="fd8088f6-e721-41cd-972e-028b012efbc9"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" valign="top">
                              <paragraph>
                                 <content styleCode="bold">You have received your full dose, if you have: </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>✓</caption>Used 1 device</item>
                                 <item>
                                    <caption>✓</caption>Given 1 spray into 1 nostril</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Additional Information</content>
                              </paragraph>
                              <paragraph>For more information on ZAVZPRET (zavegepant), visit <linkHtml href="http://www.zavzpret.com">www.zavzpret.com</linkHtml> or call 1-800-438-1985.</paragraph>
                              <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration Approved: 7/2024</paragraph>
                              <renderMultiMedia ID="id825404155" referencedObject="ID_28969b80-b9a5-4d15-8ecd-e80b0bfab0ac"/>
                              <paragraph>LAB-1546-2.0</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="b153d328-b5b0-4a44-b9ee-f25b4962d894">
                     <text>Figure A</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="d9e9ef00-464c-433b-8dd3-fbe78decc27e">
                     <text>Figure B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="e7b2fcf9-33b3-48cc-83da-ecca7910164b">
                     <text>Figure C</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_83364e5a-a47b-430b-b69d-6c791bbd5c8c">
                     <text>Figure D</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_974e56f1-5412-4eb9-b1df-caa88281cbc7">
                     <text>Figure E</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_636e0a63-4fbf-4141-b504-17bb82a2de3d">
                     <text>Figure F</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_88ebbd8d-761e-4a12-bab1-35fe0c0cca16">
                     <text>Figure G</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="d4cb6639-d524-4d90-9a25-0ad7dec1a806">
                     <text>Figure H</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_916d86ae-a8e0-4245-b21a-e4c832651167">
                     <text>Figure I</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_87873e60-5ce2-4b5a-9027-74b3ad13c5d0">
                     <text>Figure J</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_1c1e7c9f-c846-43c5-9669-38b904dedd9e">
                     <text>Figure K</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="fd8088f6-e721-41cd-972e-028b012efbc9">
                     <text>Figure L</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_28969b80-b9a5-4d15-8ecd-e80b0bfab0ac">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavegepant-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_05C0216E-B4CD-439E-8DF0-69DCB05D6390">
               <id root="e7c3573a-0165-408e-a43c-daecf1318b00"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – Nasal Spray Device Label Front Sample </title>
               <text>
                  <paragraph>Zavzpret<sup>TM</sup>
                     <br/>(zavegepant)<br/>nasal spray<br/>10 mg</paragraph>
                  <paragraph>PROFESSIONAL SAMPLE –NOT FOR SALE<br/>For intranasal use only <br/>NDC 63539-135-01<br/>Rx only</paragraph>
                  <paragraph>Do not test spray,<br/>prime or press the<br/>plunger before use.</paragraph>
                  <renderMultiMedia ID="id593057839" referencedObject="ID_2ff65eeb-fc59-42bb-9409-8a05a3ab931b"/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="ID_2ff65eeb-fc59-42bb-9409-8a05a3ab931b">
                     <text>PRINCIPAL DISPLAY PANEL – Nasal Spray Device Label Front Sample</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavzpret-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_33a0f78c-c35e-4ab0-952a-aa62110f2f14">
               <id root="a569a23c-b15a-4e81-bb42-49e7cfae8ef1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – Nasal Spray Device Label Back Sample </title>
               <text>
                  <paragraph>U.S. Pharmaceuticals<br/>Pfizer Inc.</paragraph>
                  <paragraph>LOT xxxxxxx<br/>EXP YYYY-MM</paragraph>
                  <renderMultiMedia ID="id-8833743" referencedObject="ID_139833e4-bafd-41e6-adb2-85521c9078d1"/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="ID_139833e4-bafd-41e6-adb2-85521c9078d1">
                     <text>PRINCIPAL DISPLAY PANEL – Nasal Spray Device Label Back Sample</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavzpret-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_74b6643e-2080-4226-89f5-b2521718dc1d">
               <id root="3d4b8550-5f6d-48e7-8b9f-78ef49fb5b71"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – Nasal Spray Blister Foil Label Sample </title>
               <text>
                  <paragraph>NDC 63539-135-01 <br/>Rx only<br/>
                  </paragraph>
                  <paragraph>PROFESSIONAL SAMPLE – <br/>NOT FOR SALE</paragraph>
                  <paragraph>PEEL OFF</paragraph>
                  <paragraph>Zavzpret<sub>TM </sub>
                     <br/>(zavegepant)<br/>nasal spray 10 mg</paragraph>
                  <paragraph>Each unit-dose device contains 10 mg of zavegepant.<br/>1 spray (10 mg dose) per unit.<br/>Do not test spray, prime or press the plunger<br/>before use.<br/>For Intranasal use only.<br/>Recommended dosage: See prescribing information.<br/>Storage:<br/>• Store at 20°C to 25°C (68°F to 77°F); excursions<br/>permitted between 15°C to 30°C (59°F to 86°F).<br/>• Do not freeze.<br/>• Keep the device in the sealed blister package<br/>until time of use.<br/>• Warning: Keep out of reach of children</paragraph>
                  <paragraph>Pfizer<br/>Distributed by<br/>U.S. Pharmaceuticals<br/>Pfizer Inc.<br/>New York, NY 10001</paragraph>
                  <renderMultiMedia ID="id387923567" referencedObject="ID_0de48fa2-7555-4f35-acf6-81e74d54f005"/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="ID_0de48fa2-7555-4f35-acf6-81e74d54f005">
                     <text>PRINCIPAL DISPLAY PANEL – Nasal Spray Blister Foil Label Sample</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavzpret-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_92088b07-856e-4545-939b-9cb91613bf4f">
               <id root="6c47eb21-e640-4abc-a5f2-ec9ea866ecc7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – Nasal Spray Carton Sample </title>
               <text>
                  <paragraph>PROFESSIONAL<br/>SAMPLE -<br/>NOT FOR SALE</paragraph>
                  <paragraph>NDC 63539-135-02<br/>Rx only</paragraph>
                  <paragraph>Zavzpret<sub>TM </sub>
                     <br/>(zavegepant)<br/>nasal spray 10 mg</paragraph>
                  <paragraph>This box contains:<br/>• 1 unit-dose nasal spray device <br/>containing 10 mg of zavegepant.<br/>• 1 Prescribing Information<br/>booklet.<br/>• 1 Instructions for Use Leaflet.</paragraph>
                  <paragraph>For Intranasal use only.</paragraph>
                  <paragraph>1 spray (10 mg dose) per unit.<br/>Do not test spray, prime<br/>or press the plunger<br/>before use.</paragraph>
                  <renderMultiMedia ID="id156349152" referencedObject="d7411d8e-08d0-4c62-8804-1b8164151f90"/>
               </text>
               <effectiveTime value="20250321"/>
               <component>
                  <observationMedia ID="d7411d8e-08d0-4c62-8804-1b8164151f90">
                     <text>PRINCIPAL DISPLAY PANEL – Nasal Spray Carton Sample</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zavzpret-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>